Marina Biotech (formerly known as MDRNA, Inc.) is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Marina Biotech's pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information is available at http://www.marinabio.com.

Contact Information

3830 Monte Villa Parkway
Bothell, WA 98021

tel: 425-908-3600
fax: 425-908-3650


Investor Relations

Westwicke Partners
John Woolford
tel: 413-213-0506
e-mail: ir@marinabio.com


Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $31.6M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.